Abstract Peripheral neuropathy (PN) is a major comorbidity of HIV infection that is caused in part by chronic immune activation. HIV-PN is associated with infiltration of monocytes/ macrophages to the dorsal root ganglia (DRG) causing neuronal loss and formation of Nageotte nodules. Here, we used an oral form of methylglyoxal-bis-guanylhydrazone (MGBG), a polyamine biosynthesis inhibitor, to specifically reduce activation of myeloid cells. MGBG is selectively taken up by monocyte/ macrophages in vitro and inhibits HIV p24 expression and DNA viral integration in macrophages. Here, MGBG was administered to nine SIV-infected, CD8-depleted rhesus macaques at 21 days post-infection (dpi). An additional nine SIV-infected, CD8-depleted rhesus macaques were used as untreated controls. Cell traffic to tissues was measured by in vivo BrdU pulse labeling. MGBG treatment significantly diminished DRG histopathology and reduced the number of CD68+ and CD163+ macrophages in DRG tissue. The number of recently trafficked BrdU+ cells in the DRG was significantly reduced with MGBG treatment. Despite diminished DRG pathology, intraepidermal nerve fiber density (IENFD) did not recover after treatment with MGBG. These data suggest that MGBG alleviated DRG pathology and inflammation.
Introduction
HIV-associated peripheral neuropathy (PN) affects more than half of HIV-infected individuals on durable anti-retroviral therapy (ART) (Ellis et al. 2010) . The most common type of HIV-PN is distal sensory polyneuropathy (DSP) that results in chronic, drug-resistant bilateral pain, tingling, and numbness in the extremities (Kaku and Simpson 2014; Pardo et al. 2001 ). We and others have shown that HIV-DSP is associated with chronic monocyte activation, which results in increased traffic of monocytes to the dorsal root ganglia (DRG). Monocyte activation and cell traffic to the DRG are associated with a reduction of neuronal cell density in the DRG and a Bdying back^of small, unmyelinated nerve fibers in distal skin regions (Bhangoo et al. 2009; Hahn et al. 2008; Lakritz et al. 2015a Lakritz et al. , 2015b . Importantly, HIV-DSP occurs despite effective ART (Dorsey et al. 2015; Ellis et al. 2010) .
ART drugs suppress viral RNA replication efficiently in T cells; however, these function less efficiently in macrophages due in part to lower intracellular drug concentrations in these cells (Gavegnano et al. 2013) . Additionally, many of ART drugs fail to eliminate integrated proviral DNA, particularly in macrophages (Ibanez et al. 1999; Riva et al. 2000) . Macrophages are long-lived and not susceptible to viralinduced cell lysis, making them a potent viral reservoir (Abbas et al. 2015) . Increased numbers of HIV DNA+ macrophages in the central nervous system (CNS) are associated with HIV-associated neurocognitive disorders (HAND), demonstrating the negative effect of virally infected cells even in the absence of active viral replication (Williams et al. 2001) . Additionally, even when viral replication is suppressed with ART, monocytes and macrophages remain chronically activated and are thought to contribute to comorbidities including HAND, cardiovascular disease, and neuropathic pain (Burdo et al. 2015) . Targeting persistently infected and/or activated macrophages is a major hurdle in combating HIV-associated diseases. Viral replication in macrophages in DRG is present in some animals, but not all. Additionally, the number of virally infected cells in the DRG does not correlate with pathology, suggesting that viral proteins are not the main source of neuronal death (Lakritz et al. 2015a ). Identifying drugs that will target viral replication and macrophage activation is likely to help treat and prevent HIV-associated comorbidities.
Methyl-bis-guanylhydrazone (MGBG) is a polyamine analog that interferes with polyamine biosynthesis by inhibiting S-adenosyl-methionine decarboxylase (SAMDC) (Williams-Ashman and Schenone 1972) . This process is required for cell differentiation and proliferation, and thus, MGBG has been studied as an anti-tumor cell proliferation drug (Janne et al. 1985) . Virally infected macrophages treated with MGBG in vitro displayed reduced integration of proviral DNA compared to control macrophages, although the levels of total intracellular DNA were unchanged (Jin et al. 2015) . MGBG is selectively taken up by monocyte/macrophages in vitro and inhibits activation by depleting the intracellular pool of spermine and spermidine (Kaczmarek et al. 1992; Messina et al. 1992) . Depletion of these intracellular polyamines results in prevention of alternatively activated M2 macrophage induction and also inhibits LPS induced cytokine production from M1 macrophages (Van den Bossche et al. 2012) . Thus, MGBG could function to reduce viral replication in monocytes/macrophages through blocking viral integration and will reduce alternative activation of these cells through polyamine depletion in vivo. We have recently shown that MGBG can reduce cardiovascular inflammation, carotid intima-media thickness (CIMT), and fibrosis that correlated with a decrease in number of macrophage in SIV-infected macaques (Walker et al. 2017) .
Here, we aimed to specifically target monocytes and macrophages with MGBG in a primate model of HIV-PN in an attempt to reduce DRG pathology associated with macrophage differentiation and trafficking (Lakritz et al. 2015a) . Eighteen rhesus macaques were infected with SIVmac251 and CD8 depleted to allow for rapid disease progression. Nine animals received an oral form of MGBG and the remaining nine were untreated controls. Here, we show that MGBG treatment results in less severe DRG pathology by reducing numbers of macrophages in tissue.
Methods
Animals, viral infection, and CD8 lymphocyte depletion Eighteen male rhesus macaques (Macaca mulatta) were utilized in this study. All animals were inoculated intravenously with SIVmac251 (a generous gift from Dr. Ronald Desrosiers, University of Miami) and administered 10 mg/kg of anti-CD8 antibody subcutaneously at day 6 after infection and 5 mg/kg intravenously at days 8 and 12 after infection in order to achieve rapid AIDS. The human anti-CD8 antibody was provided by the NIH Non-human Primate Reagent Resource (RR016001, AI040101). Animals were sacrificed between 55 and 89 days post-infection (dpi) based on progression of disease or termination of the study. They were anesthetized with ketamine-HCl and euthanized by an intravenous pentobarbital overdose and exsanguinated. The diagnosis of simian AIDS was determined post-mortem by the presence of opportunistic infections, including SIV giant cell pneumonia, CMV pneumonia, giant cell encephalitis, pneumocystis carinii, and lymphoma.
MGBG administration
Nine animals received 30 mg/kg of MGBG (provided by Pathologica, LLC; formulated as flavored syrup by Wedgewood Pharmacy, Swedesboro, NJ) daily beginning at 21 dpi. Previous experiments demonstrated that a daily dose of 30 mg/kg of MGBG was able to achieve an effective concentration of 0.7 μM in tissue and plasma (data not shown).
BrdU administration
5-bromo-2'-deoxyuridine (BrdU) was administered as a slow bolus intravenous injection at a dose of 60 mg/kg body weight as previously described (Burdo et al. 2010) . BrdU was administered on 7, 19, and 56 dpi and 24 h prior to necropsy.
Plasma viral load quantification
Plasma SIV-RNA was quantified using real-time PCR for all animals used in this study, as previously described (Walker et al. 2017) . EDTA plasma (500 μL) was collected, and SIV virions were pelleted by centrifugation at 20,000×g for 1 h. The threshold sensitivity was 100 copy Eq/ml, with an average interassay coefficient variation of less than 25%.
Intraepidermal nerve fiber density measurements
Skin biopsies (3 mm) were taken in all SIV+ animals at 20 dpi (pre-drug) and at necropsy (post-drug). Biopsies were taken near the sural innervation site just distal to the lateral malleolus and were fixed in Zamboni's fixative. Fifty-micrometer-thick sections were stained with a panaxonal marker (anti-PGP 9.5 at 1:10,000 dilution; ABD Serotec). Nerve fiber length (mm) per volume of epidermis (mm 3 ) (intraepidermal nerve fiber density, IENFD) was quantified using computer software (Space balls program; Microbrightfield Bioscience) as previously described (Lakritz et al. 2015a (Lakritz et al. , 2015b .
Necropsy and histopathology
Animals were necropsied immediately following death, and representative sections of all major organs were collected, fixed in 10% neutral buffered formalin (NBF), embedded in paraffin, and sectioned at 5 μm. Hematoxylin and eosinstained sections of DRG were evaluated blindly for histopathologic lesions by a board-certified veterinary anatomic pathologist (ADM) and scored based on the presence and severity of infiltrating mononuclear cells, neuronophagia, and Nageotte nodules as previously described (Burdo et al. 2012; Lakritz et al. 2015a) . Overall pathology was scored on a scale of 0 to 3 at increments of 0.5 via the following criteria: (0) no significant findings; (1) mild: scattered infiltrating mononuclear cells with rare evidence of neuronophagia and/or neuronal loss; (2) moderate: increased numbers of infiltrating mononuclear cells with occasional neuronophagia and/or neuronal loss; and (3) severe: abundant infiltrating mononuclear cells, frequent neuronophagia, and neuronal loss were all present.
Immunohistochemistry and quantification satellite cells in DRGs
DRG sections were stained with either the panmacrophage marker anti-CD68 (Clone KP1, Dako, Carpinteria, CA), the scavenger receptor anti-CD163 (Clone MCA1853, Serotec, Raleigh, NC), the early inflammatory marker anti-MAC387 (Clone M0747, Dako, Carpinteria, CA), the anti-BrdU (Clone M0744, Dako, Carpinteria, CA), or the T lymphocyte marker anti-CD3 (Clone A0452, Dako, Carpinteria, CA) as previously described (Burdo et al. 2012; Lakritz et al. 2015a) . For quantitation of monocyte/macrophage and T cell populations by immunohistochemical analyses, at least eight non-overlapping fields at ×200 magnification were quantitated per DRG tissue as previously described (Burdo et al. 2012; Lakritz et al. 2015a ). Data were expressed as mean ± standard error of the mean (SEM).
Statistical methods
Prism version 5.0f (GraphPad Software, Inc., San Diego, CA) software was used for statistical analyses. MannWhitney T tests were used to detect variation in cell numbers between untreated and MGBG-treated rhesus macaques. Wilcoxon matched-pairs signed rank test was used to detect a change of IENFD within an individual over time. A p value of <0.05 was considered significant for all analysis performed.
Results

MGBG treatment diminishes overall DRG pathology
Eighteen SIV-infected, CD8-depleted rhesus macaques were used in this study (Table 1) . Nine of the animals received MGBG starting at 21 dpi. The remaining nine animals were untreated SIV-infected controls. All animals used in these studies were male, and the age of the placebo (5.6 ± 0.7 years) and the MGBG-treated (4.6 ± 0.1 years) group was not statistically different (p = 0.2). All animals were sacrificed between 55 and 89 dpi. The viral load at necropsy in the MGBG-treated group was 7.38 ± 0.25 and 7.58 ± 0.24 copies/ml in the control group (p = 0.61; Table 1 ).
Histopathology of lumbar, sacral, and thoracic dorsal root ganglia was assessed for the presence and degree of satellitosis, neuronophagia, and Nageotte nodules and is reported in Table 1 . Overall DRG pathology was ranked on a scale of zero to three as previously described (Lakritz et al. 2015a (Lakritz et al. , 2015b ) with a score of zero indicating no significant findings and a score of three indicating severe pathology. Treatment with MGBG significantly reduced the overall DRG pathology from an average score of 1.4 ± 0.2 in control animals to 0.9 ± 0.1 (p < 0.05; Fig. 1) . Notably, none of the MGBG-treated animals developed Nageotte nodules. Additionally, the degree of satellitosis and neuronophagia never reached a pathology score above 1.5 (mild-moderate) in MGBG-treated animals compared to untreated which ranged from a score of 1 (mild) to 2.5 (moderate-severe) ( Table 1) .
MGBG treatment decreases the number of macrophages in the DRG
We sought to determine if MGBG affected immune activation in the DRG and the composition of macrophages that surround the DRG. We have previously shown that the numbers of CD68+, CD163+, and MAC387+ macrophages are increased in DRG tissues of SIV-infected animals compared to uninfected animals. Additionally, elevated numbers of CD68+ and MAC387+ macrophages in DRG tissue were associated with severe pathology (Lakritz et al. 2015a ). Here, we sought to determine if MGBG treatment would affect resident and recently trafficked macrophages. We investigated the number of CD68+, CD163+, and MAC387+ macrophages in the DRG. CD163 is a hemoglobin-haptoglobin scavenger receptor that has been associated with an M2 (alternative activation) phenotype and can also overlap with the CD68+ macrophage population, which is considered to be a marker of mature tissue macrophages (Etzerodt and Moestrup 2013) . MAC387 is expressed by recently infiltrated, inflammatory M1-like (classically activated) monocytes/macrophages and does not colocalize with CD68 or CD163 (Soulas et al. 2011) . Here, we found that the number of CD68+ macrophages in the DRG decreased significantly with MGBG treatment (784.3 ± 86.8 versus 473.9 ± 44.2 cells/mm 2 ; p < 0.01; Fig. 2a-c) . Additionally, MGBG reduced the number of CD163+ macrophages in DRG (789 ± 107.5 versus 369.5 ± 45.7 cells/mm 2 ; p < 0.01; Fig. 2d-f ). The number of MAC387+ macrophages, while not statistically significant, did trend towards a decrease with MGBG treatment (133.0 ± 15.6 versus 91.9 ± 11.4 cells/mm 2 ; p = 0.06; Fig. 2g-i) . Next, we assessed cell traffic to the DRG using BrdU labeling (Goto et al. 2003) . We have previously shown that increased monocyte traffic to the DRG was associated with severe pathology and a loss of IENFD. The majority (78.1%) of BrdU+ cells in the DRGs were found to be MAC387+ macrophages (Lakritz et al. 2015a ). Here, we found that MGBG significantly reduced traffic of BrdU+ cells (78.3 ± 6.3 versus 41.9 ± 4.3 cells/mm 2 ; p < 0.0001; Fig. 2j-l) .
Finally, we examined the number of CD3+ T lymphocytes in the DRG in both MGBG-treated and untreated groups. We have previously shown that the number of T cells in the DRG did not increase with SIV infection (compared to uninfected animals) (Burdo et al. 2012; Lakritz et al. 2015a ). We found that there was no change Mod moderate a Timed or paired sacrificed Fig. 1 Overall DRG pathology is reduced in MGBG-treated animals compared to controls. Overall DRG pathology was scored on a scale of zero (no significant findings) to three (severe pathology) at increments of 0.5 in lumbar, sacral, and thoracic regions and were averaged in each animal. Pathology was scored based on the degree and presence of satellitosis, neuronophagia, and Nageotte nodules. Bars represent the average overall DRG pathology mean ± SEM. Groups were compared with a Mann-Whitney T test. *p < 0.05 in the number of CD3+ T cells with MGBG treatment (168.1 ± 18.1 versus 122.9 ± 11.1 cells/mm 2 ; p = 0.08; Fig. 2m-o) , suggesting that MGBG had no effect on T cells. There is no regeneration of IENFD with MGBG treatment
All animals received skin biopsy punches before MGBG treatment (20 dpi) and at necropsy to assess if MGBG treatment would allow for or prevent regeneration of IENFD. We have previously reported an early decline in IENFD following SIV infection that never recovers to baseline levels (Lakritz et al. 2015a) . As expected, IENFD in SIV-infected untreated animals did not change between 20 dpi and necropsy (298.8 ± 50.9 IENFD at 20 dpi versus 304.8 ± 47.1 IENFD at necropsy; p = 0.84; Fig. 3a) . Interestingly, MGBG-treated animals had a significant additional loss of IENFD after drug treatment was initiated at 21 dpi. IENFD in the MGBG-treated group decreased from 551.8 ± 73.3 IENFD at 20 dpi to 387.8 ± 53.0 IENFD at necropsy (p < 0.05; Fig. 3b ). We suspect that this is because macrophages are required for peripheral nerve regeneration and MGBG targets these M2 repair macrophages (Barrette et al. 2008; Niemi et al. 2013) . MGBG treatment in the absence of SIV infection did not significantly affect the IENFD (369.3 ± 108.0 IENFD at pre-drug versus 291.7 ± 113.3 IENFD at necropsy; p = 0.75; data not shown). This demonstrates that MGBG is not neurotoxic and that the drug's effect on macrophages combined with SIV infection is the cause of IENFD reduction.
Discussion
In a recent study, we showed that MGBG treatment in SIVinfected macaques reduced cardiovascular inflammation, CIMT, and fibrosis that correlated with a decrease in number of macrophages (Walker et al. 2017) . Here, we found that MGBG administration in a rhesus model of HIV-PN diminished DRG pathology with reduced numbers of CD68+ and CD163+ macrophages. We have previously shown that the number of CD68+ and CD163+ macrophages in DRG tissue increased after SIV infection. Additionally, we have shown that macrophage cell traffic to the DRG is associated with severe DRG pathology and a greater loss of IENFD (Lakritz et al. 2015a) . Monocyte traffic to the DRG appears to be a driving force of formation of Nageotte nodules, neuronophagia, and DRG pathology. When cell traffic was blocked with an anti-VLA-4 antibody, natalizumab, on the day of infection, there was a reduction in these pathological processes. However, blocking cell traffic during late infection did not completely prevent formation of Nageotte nodules suggesting that Nageotte nodules and neuronophagia form during early infection (Lakritz et al. 2016) . Here, we found that MGBG treatment reduced BrdU+ cell traffic to the DRG and reduced tissue pathology. Despite the reduction of cell traffic and pathology in the DRGs, we did not observe regeneration of IENFD in the footpad. It has been previously shown that IENFD does regenerate in the setting of HIV infection, but was slowed (Hahn et al. 2007 ). Loss of IENFD in the SIV-infected CD8 depleted macaque model occurs early after infection (dpi 8-21) and never recovers to the baseline level (Lakritz et al. 2015a) . Because MGBG was not administered until 21 dpi, where significant loss of IENFD has already occurred, it may not be reversible. Early MGBG treatment may be warranted to maintain IENFD in addition to protecting DRGs. Macrophages play a role in tissue remodeling and peripheral nerve regeneration (Gaudet et al. 2011) . We suspect that the diminished numbers of alternatively activated macrophages in MGBG-treated animals prevented peripheral nervous system (PNS) recovery. Polyamines, which are depleted with MGBG treatment, aid in sciatic nerve regeneration in vivo and promote axonal regeneration in vitro (Deng et al. 2009; Kauppila 1992) . Additionally, macrophage accumulation around injured PNS nerves is an important step in regeneration. Macrophages are responsible for removing myelin and axonal debris from the injury site. Depleting macrophages delays both Wallerian degeneration and regeneration of axons, demonstrating that macrophages play a multitude of roles in PNS injury and recovery (Barrette et al. 2008; Chen et al. 2015; Gaudet et al. 2011; Niemi et al. 2013) . The lack of IENFD regeneration in MGBG-treated animals implies an additional impairment (secondary to SIV infection) that consists of a lack of tissueregenerative macrophages, polyamines, and/or ongoing injury assessed with a Wilcoxon matched-pairs signed rank test. A p value less than 0.05 was considered significant due to sustained viral load and cytokines despite MGBG treatment. Since MGBG decreased DRG pathology and inflammation when treatment was begun at dpi 21, studies are now being performed to examine the effects of MBGB on IENFD when treatment is initiated earlier.
It is thought that HIV-PN may be caused by direct neurotoxicity of viral proteins and by indirect damage of cytokines and chemokines that are secreted by activated myeloid cells (Pardo et al. 2001) . HIV-and SIV-PN occur even when viral replication is suppressed and non-neurotoxic ART drugs are used (Dorsey et al. 2015) . Therefore, it is possible that immune activation that occurs with or without active viral replication is a main cause of persistent PNS damage. We have previously shown that elevated plasma sCD163 and regulated upon activation, normal T cell expressed and secreted (RANTES) (both of which are associated with myeloid cell activation and chemotaxis) correlates with reduced IENFD in SIV+ macaques (Lakritz et al. 2015b) . HIV-PN does not typically respond to pain medicine (Phillips et al. 2010; Pillay et al. 2015) . Thus, identifying treatment options that target the cause of damage to the nerves or DRG neurons has great clinical implications.
Few drugs specifically target monocyte and macrophage activation as therapy for HIV-PN. One drug that may improve PNS pathology in HIV+ patients is maraviroc. Maraviroc is a CCR5 inhibitor that blocks viral entry into CCR5+ cells Piotrowska et al. 2016 . RANTES (the ligand for CCR5) and CCR5+ cells in the DRG are elevated after SIV infection and are associated with SIV-PN pathologies Lakritz et al. 2015b . Additionally, in vitro maraviroc treatment to DRG neurons inhibited gp120-induced tumor necrosis factor-alpha expression and thus reduced neurotoxicity (Moss et al. 2015) . Cenicriviroc (CVC), which is currently in clinical trials for HIV treatment, targets both CCR5 and CCR2 (Kramer et al. 2015; Thompson et al. 2016) . The ligand for CCR2 is CCL2 or monocyte chemoattractant protein-1 (MCP-1) is elevated in SIV+ DRG (Lakritz et al. 2015b ) and most likely plays a role in recruiting inflammatory CCR2+ monocytes to the tissue. Additionally, CCR2-CCL2 interaction has been implicated in models of neuropathic pain (Biber et al. 2014; Thacker et al. 2009 ). It is unclear if CVC treatment will have a beneficial effect on PNS nerve pathologies.
MGBG is specifically taken up by monocytes and macrophages inhibiting HIV integration in vitro, although the exact mechanism of this phenomenon is not clear (Jin et al. 2015) . There was no difference in plasma viral load between the placebo and MGBG-treated animals, which was expected since most plasma virus is determined from T cells and not monocytes and MGBG only effects HIV replication in myeloid cells. MGBG has been well studied as a potent inhibitor of SAMDC and therefore depletes the intracellular polyamine pool (Corti et al. 1974; Williams-Ashman and Schenone 1972) . Polyamines are regulators of macrophage activation, are needed for alternative macrophage (M2) polarization, and can inhibit M1-cytokine production (Van den Bossche et al. 2012) . In this study, we found that MGBG significantly reduced the number of CD163+ (M2) macrophages, but not the number of MAC387+ (M1-like) macrophages in the DRG, supporting a mechanism of MGBG inhibition of M2 activation.
Identifying drugs that target myeloid cells to reduce their traffic and activation during HIV and SIV disease pathogenesis is important to prevent HIV comorbidities. However, one must be careful to not completely block macrophage function, as they can play essential roles in innate immunity and tissue remodeling, as demonstrated by the lack of IENFD regeneration in this study. Future studies should seek to understand the diverse role of different macrophage phenotypes and identify drugs that specifically target destructive and inflammatory macrophages. Treatment with MGBG before PNS damage begins would likely have a greater preventative impact on the development of PN. Additionally, using MGBG in conjunction with ART to reduce monocyte/macrophage activation and viral replication may also be beneficial. In this study, we did not see an effect on plasma viral load as expected since MGBG only targets HIV integration in myeloid cells and not T cells. Suppressing viral replication with ART and reducing monocyte activation with MGBG may be a successful combination to control disease progression and prevent inflammation-induced comorbidities, and these studies are currently underway.
